Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Accounts Payables: 2010-2024

Historic Accounts Payables for OptimizeRx (OPRX) over the last 15 years, with FY2024 value amounting to $2.2 million.

  • OptimizeRx's Accounts Payables fell 2603.49% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 2603.49%. This contributed to the annual value of $2.2 million for FY2024, which is 318.81% down from last year.
  • Latest data reveals that OptimizeRx reported Accounts Payables of $2.2 million as of FY2024, which was down 318.81% from $2.2 million recorded in FY2023.
  • OptimizeRx's 5-year Accounts Payables high stood at $2.2 million for FY2023, and its period low was $606808.0 during FY2021.
  • Moreover, its 5-year median value for Accounts Payables was $1.5 million (2022), whereas its average is $1.4 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first soared by 15543.15% in 2022, then crashed by 318.81% in 2024.
  • OptimizeRx's Accounts Payables (Annual) stood at $618250.0 in 2020, then decreased by 1.85% to $606808.0 in 2021, then skyrocketed by 155.43% to $1.5 million in 2022, then soared by 43.68% to $2.2 million in 2023, then dropped by 3.19% to $2.2 million in 2024.
  • Its Accounts Payables stands at $2.2 million for FY2024, versus $2.2 million for FY2023 and $1.5 million for FY2022.